Core Viewpoint - The newly established provincial state-owned asset disposal service platform successfully completed its first asset disposal transaction, achieving a premium rate of 43.6% on the sale of state-owned equity, significantly enhancing the efficiency of state asset disposal [1] Group 1: Asset Disposal Platform - The provincial state-owned asset disposal service platform was established to centralize the disposal of state-owned assets, including office equipment, real estate, equity, and debt, ensuring the safety, integrity, and appreciation of these assets [1] - Since October 1 of last year, state-owned assets are no longer disposed of by individual units but are instead managed by the new platform, which is a pioneering initiative at the provincial level in the country [1] Group 2: First Transaction Details - The first asset disposed of by the platform was a 20% state-owned equity stake in Sichuan Dingjian Animal Pharmaceutical Co., valued at 6,119,180 yuan after auditing and evaluation [1] - The equity stake was sold through a public auction at the provincial government’s service and public resource trading center, ultimately fetching 8,790,000 yuan, resulting in a premium of 43.6% [1] Group 3: Implementation of New Policies - Following the introduction of new policies for the disposal of state-owned assets in the second half of last year, various units have been strictly adhering to regulations, submitting proposed disposals for approval to the provincial government [2] - A significant number of office equipment, real estate, and equity assets are currently in the preliminary disposal phase under the centralized management of the provincial state-owned asset disposal service platform [2]

证券代码：603739 证券简称：蔚蓝生物公告编号：2025-056 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 担保对象及基本情况 ■ ● 累计担保情况 ■ 一、担保情况概述 （二）内部决策程序 上述担保事项已经公司2025年4月25日召开的第五届董事会第十六次会议审议通过，并经公司于2025年5 月16日召开的2024年年度股东会批准。具体内容详见公司分别于2025年4月26日、2025年5月17日在上海 证券交易所网站披露的《青岛蔚蓝生物股份有限公司关于2025年度对外担保额度预计的公告》（公告编 号：2025-011）、《青岛蔚蓝生物股份有限公司2024年年度股东会决议公告》（公告编号：2025- 022）。 二、被担保人基本情况 ■ 三、担保协议的主要内容 1、债权人：中国光大银行股份有限公司青岛城阳支行 6、保证期间：自具体授信业务合同或协议约定的受信人履行债务期限届满之日起三年。 7、保证范围：受信人在主合同项下应向授信人偿还或 ...

Core Viewpoint - The company has approved several key resolutions during its board meeting, including the government acquisition of idle assets and the establishment of a high-end formulation production and R&D base, which are aimed at optimizing asset structure and enhancing operational efficiency [1][2][3][4][6][10]. Group 1: Government Acquisition of Idle Assets - The board approved the acquisition of idle assets from the Lanzhou Biological Pharmaceutical Factory and Lanzhou Zhongmu Pharmaceutical Technology Co., Ltd. by the Lanzhou Chengguan District People's Government, with a total compensation amount of 228.9782 million yuan [2][10][12]. - The assets being acquired include state-owned land, buildings, and equipment located at No. 2 Yanchang Road, Chengguan District, Lanzhou, which have been assessed as idle [10][12][32]. - The compensation amount is based on an evaluation report from Gansu Fangjia Real Estate Asset Appraisal Co., Ltd., with the land and buildings valued at 218.1045 million yuan and equipment at 10.8737 million yuan [12][20]. Group 2: High-end Formulation Production and R&D Base - The board approved the implementation of a high-end formulation production and R&D base project by its wholly-owned subsidiary, Zhongmu Nanjing Animal Pharmaceutical Co., Ltd., with a total planned investment of 299.6186 million yuan [3][6]. - The funding for the project will come from the subsidiary's own funds and self-raised funds, aimed at enhancing the company's product structure and promoting the development of its pet business [3][6]. Group 3: Governance and Management Updates - The board approved the revision of the Comprehensive Budget Management Measures, which aims to improve the company's financial management practices [4][5]. - The board also agreed to adjust the Strategic Committee to include ESG (Environmental, Social, and Governance) responsibilities, enhancing the company's governance structure and commitment to sustainable development [6][7]. - A new Market Value Management System was also approved to better manage the company's market capitalization [7].

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for its subsidiary to register two new veterinary drugs for dogs and cats, indicating a significant advancement in its product offerings [1] Group 1 - The company, Blue Biological (603739), announced that its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., has successfully applied for the registration of "Fluralaner Drops (for Dogs)" and "Fluralaner Drops (for Cats)" as Class II new veterinary drugs [1] - The Ministry of Agriculture and Rural Affairs has issued the "New Veterinary Drug Registration Certificate" for these products, which marks a key milestone in the company's development strategy [1]